RU2020105102A - Новая композиция пероральной лекарственной формы энзалутамида и способ ее получения - Google Patents

Новая композиция пероральной лекарственной формы энзалутамида и способ ее получения Download PDF

Info

Publication number
RU2020105102A
RU2020105102A RU2020105102A RU2020105102A RU2020105102A RU 2020105102 A RU2020105102 A RU 2020105102A RU 2020105102 A RU2020105102 A RU 2020105102A RU 2020105102 A RU2020105102 A RU 2020105102A RU 2020105102 A RU2020105102 A RU 2020105102A
Authority
RU
Russia
Prior art keywords
enzalutamide
dosage form
oral dosage
pharmaceutical composition
new pharmaceutical
Prior art date
Application number
RU2020105102A
Other languages
English (en)
Russian (ru)
Inventor
Шах ДХАРМЕШ МАХЕНДРАБХАЙ
Бадигер АРАВИНД МАНАППА
Чокси РАКШИТ КЕТАНБХАЙ
Пател БХАВЕШ НАГИНБХАЙ
Салункхе ПИЮША ШАРАД
Сони НИРАДЖ РАМНИВЕДАН
Original Assignee
Бдр Фармасьютикалз Интернэшнл Прайвит Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64950639&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2020105102(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бдр Фармасьютикалз Интернэшнл Прайвит Лимитед filed Critical Бдр Фармасьютикалз Интернэшнл Прайвит Лимитед
Publication of RU2020105102A publication Critical patent/RU2020105102A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2020105102A 2017-07-04 2017-11-21 Новая композиция пероральной лекарственной формы энзалутамида и способ ее получения RU2020105102A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201721023465 2017-07-04
IN201721023465 2017-07-04
PCT/IB2017/057273 WO2019008426A1 (fr) 2017-07-04 2017-11-21 Nouvelle composition de forme galénique orale d'enzalutamide et procédé de fabrication de celle-ci

Publications (1)

Publication Number Publication Date
RU2020105102A true RU2020105102A (ru) 2021-08-04

Family

ID=64950639

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2020105102A RU2020105102A (ru) 2017-07-04 2017-11-21 Новая композиция пероральной лекарственной формы энзалутамида и способ ее получения

Country Status (7)

Country Link
BR (1) BR112020000207A2 (fr)
CL (1) CL2020000017A1 (fr)
MX (1) MX2020000213A (fr)
PH (1) PH12020500045A1 (fr)
RU (1) RU2020105102A (fr)
WO (1) WO2019008426A1 (fr)
ZA (1) ZA202000609B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR118925A1 (es) * 2020-05-13 2021-11-10 Novocap S A Solución líquida concentrada de antiandrógenos no esteroideos y procedimiento para preparar la solución

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201891397A1 (ru) * 2014-02-05 2019-03-29 Лек Фармасьютикалз Д.Д. Твердые фармацевтические композиции антагонистов рецепторов андрогенов

Also Published As

Publication number Publication date
MX2020000213A (es) 2020-08-17
WO2019008426A1 (fr) 2019-01-10
BR112020000207A2 (pt) 2020-07-07
PH12020500045A1 (en) 2020-11-09
CL2020000017A1 (es) 2020-05-22
ZA202000609B (en) 2021-08-25

Similar Documents

Publication Publication Date Title
EA013161B1 (ru) Дозированная форма для перорального применения
CA2903440C (fr) Compositions solides comprenant un activateur de glucokinase et procedes de fabrication et d'utilisation associes
EP2468361B1 (fr) Formulations de vildagliptine
JP2011098964A5 (fr)
RU2011112362A (ru) Твердые препаративные формы оспемифена
JP2010534220A5 (fr)
EA035667B1 (ru) Фармацевтическая композиция от нейропатической боли
TW201322979A (zh) 醫藥組成物
CA2764172A1 (fr) Antagoniste du recepteur de la thrombine et comprime de clopidogrel a dose fixe
RU2020105102A (ru) Новая композиция пероральной лекарственной формы энзалутамида и способ ее получения
JP6393549B2 (ja) ビタミンｂ１２含有組成物
WO2011080706A1 (fr) Solubilité améliorée de la ziprasidone
CN109963565B (zh) 一种药物组合物及其制备方法
JP2014522856A (ja) アルテロランおよびピペラキンの安定した投与形態物
KR20100103629A (ko) 레베티라세탐을 함유하는 코팅된 방출연장형 약제 조성물
US20080193537A1 (en) Morphine Sulfate Formulations
AU2009230676A1 (en) Delayed release compositions of duloxetine
RU2014124118A (ru) Фармацевтические препараты, включающие аторвастатин и глимепирид
EP3796899B1 (fr) Nouvelle composition pharmaceutique de tamsulosine et de dutastéride
JP6216408B2 (ja) 固体剤形で非常に難溶性の薬物を調製する方法
US20170020880A1 (en) Pharmaceutical compositions of trametinib
WO2011096953A1 (fr) Formulation orale d'antidépresseur avec une charge réduite en excipients
US20040208932A1 (en) Stabilized paroxetine hydrochloride formulation
WO2010062996A2 (fr) Composition de ribavirine
WO2016139681A2 (fr) Composition pharmaceutique de tizanidine et son procédé de préparation

Legal Events

Date Code Title Description
HE9A Changing address for correspondence with an applicant